Title : Concurrent use of metformin enhances the efficacy of EGFR-TKIs in patients with advanced EGFR-mutant non-small cell lung cancer-an option for overcoming EGFR-TKI resistance.

Pub. Date : 2021 Mar

PMID : 33889509






7 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Concurrent use of metformin enhances the efficacy of EGFR-TKIs in patients with advanced EGFR-mutant non-small cell lung cancer-an option for overcoming EGFR-TKI resistance. Metformin epidermal growth factor receptor Homo sapiens
2 Concurrent use of metformin enhances the efficacy of EGFR-TKIs in patients with advanced EGFR-mutant non-small cell lung cancer-an option for overcoming EGFR-TKI resistance. Metformin epidermal growth factor receptor Homo sapiens
3 Metformin can also augment apoptosis effect of these TKI-resistant cells to EGFR-TKIs. Metformin epidermal growth factor receptor Homo sapiens
4 Further analysis revealed that metformin obviously prolonged the median PFS2 of osimertinib treatment among patients who progressed to prior line EGFR-TKIs due to secondary EGFR T790M mutation (cohort B). Metformin epidermal growth factor receptor Homo sapiens
5 Further analysis revealed that metformin obviously prolonged the median PFS2 of osimertinib treatment among patients who progressed to prior line EGFR-TKIs due to secondary EGFR T790M mutation (cohort B). Metformin epidermal growth factor receptor Homo sapiens
6 Conclusions: Our study suggest that concurrent use of metformin could be beneficial to EGFR-mutant NSCLC patients treated with either first-line EGFR-TKIs or second-line osimertinib. Metformin epidermal growth factor receptor Homo sapiens
7 Conclusions: Our study suggest that concurrent use of metformin could be beneficial to EGFR-mutant NSCLC patients treated with either first-line EGFR-TKIs or second-line osimertinib. Metformin epidermal growth factor receptor Homo sapiens